[ TRANSACTION RECORD ]

The Carlyle Group Investment in Vantive — 2024

VERIFIED VECTOR ID: 001543 · tx-071
M SOURCE NODE — FUNDER
Finance United States
$3,800,000,000
EQUITY
13/08/2024
Q DESTINATION NODE — RECIPIENT
Company United States
Amount (USD)
$3.8B
Flow Type
EQUITY
Transaction Date
13/08/2024
Primary Source
Funder Profile [ M ]
AUM 426000
HQ Location United States
Sector Finance
Recipient Profile [ Q ]
Entity Vantive
Entity Type Company
Jurisdiction United States
Intelligence Note

The Carlyle Group entered into an agreement to acquire Baxter’s Kidney Care segment, Vantive, for 3.8 billion dollars. The transaction is designed to establish Vantive as an independent leader in global renal therapy and hospital solutions. This deal represents a major institutional deployment of capital into the resilient healthcare and medical device sector.